This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Farydak
  • /
  • Efficacy of Panobinostat in Patients With Relapsed...
Clinical trial

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (MACS1271)

Read time: 1 mins
Last updated:1st Jun 2010

This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.


Study Type: Interventional
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Enrollment: 55
Study Start Date: June 2010
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
panobinostat + bortezomib & dexamethasone


Related journal: PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Category Value
Study start date 2010-06-01

View full details